+

WO1998008490A1 - Solid coprecipitates for enhanced bioavailability of lipophilic substances - Google Patents

Solid coprecipitates for enhanced bioavailability of lipophilic substances Download PDF

Info

Publication number
WO1998008490A1
WO1998008490A1 PCT/US1997/015072 US9715072W WO9808490A1 WO 1998008490 A1 WO1998008490 A1 WO 1998008490A1 US 9715072 W US9715072 W US 9715072W WO 9808490 A1 WO9808490 A1 WO 9808490A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
tpgs
coprecipitate
solid
lipophilic substance
Prior art date
Application number
PCT/US1997/015072
Other languages
French (fr)
Inventor
Shimon Amselem
Original Assignee
Pharmos Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11917696A external-priority patent/IL119176A/en
Priority claimed from US08/833,076 external-priority patent/US5891469A/en
Application filed by Pharmos Corporation filed Critical Pharmos Corporation
Priority to JP51187998A priority Critical patent/JP2001523221A/en
Priority to CA002264718A priority patent/CA2264718C/en
Priority to AU42373/97A priority patent/AU730216B2/en
Priority to EP97940639A priority patent/EP1017366A4/en
Publication of WO1998008490A1 publication Critical patent/WO1998008490A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • compositions comprising solid coprecipitates for improved oral delivery and enhanced bioavailability of lipophilic substances, and to methods for the preparation and use of these compositions. More particularly, these compositions include tocopherol polyethyleneglycol succinate powdered coprecipitates of lipophilic substances.
  • Lipophilic substances possessing low water solubility often have poor oral bioavailability. These substances, being hydrophobic by nature, show wetting difficulties and poor dissolution. These properties obviously represent a rate-limiting step in their absorption from solid oral dosage forms and, in turn, cause a subsequent reduction in their bioavailability.
  • these lipophilic substances are usually administered in the form of liquid preparations dissolved in edible oils or formulated in oil-in-water emulsions or microemulsions. Even in these formulations, however, the oral bioavailability of many of them is still very low. Thus, even today, there remains an unresolved need for safe and useful formulations that provide enhanced oral bioavailability for such substances.
  • Cannabinoids are one example of a family of lipophilic substances with very poor water solubility.
  • Cannabinoids such as ⁇ '-tetrahydrocannabinol ( ⁇ '-THC) ,
  • ⁇ 6 -tetrahydrocannabinol ⁇ 6 -THC
  • ⁇ 9 -tetrahydrocannabinol ⁇ 9 -THC
  • cannabinol cannabidiol
  • cannabidiol cannabidiol
  • THC tetrahydrocannabinol
  • Dexanabinol (also denoted HU-211) , is disclosed in US Patents 4,876,276 and 5,521,215, as a synthetic non- psychoactive cannabinoid with novel neuroprotective activity in the multiple-action treatment of brain damage associated with stroke, head trauma, and cardiac arrest.
  • Dexanabinol is a very lipophilic compound which is practically insoluble in water (less than 50 ⁇ g/ml) and, like other lipophilic drugs, exhibits poor oral bioavailability.
  • Coenzyme Q10 chemically named 2,3-dimethoxy-5-methyl-6- decaprenyl-l,4-benzoquinone and also known by the names Ubiquinone or Vitamin K, is classified as a fat-soluble quinone, a naturally occurring enzyme. It has been identified as an essential component of the mitochondrial respiratory chain, and, thus, a necessary part of a cell's energy production. More particularly, it constitutes a redox-link between flavoproteins and cytochromes and acts as an electron shuttle controlling the efficiency of oxidative phosphorylation. It is a very lipophilic compound and practically insoluble in water due to its long side chain of 10 isoprenoid units.
  • CoQIO has been previously identified as a natural antioxidant with potential use as a dietary supplement to protect against age-related degeneration and as an adjuvant vitamin to prevent or treat many disease states.
  • Supplementary Coenzyme Q10 has reportedly shown beneficial influences in a variety of conditions or diseases, including: periodontal disease, certain blood circulation diseases, impaired memory, fatigue, irregular heartbeat, high blood pressure, immune system impairment, and the aging process.
  • the recommended daily allowance for coenzyme Q10 has not been determined. Most experts agree, however, that the daily requirement lies somewhere between 30 and 60 milligrams. When treating illnesses, dosages of 100 to 300 milligrams are commonly used.
  • the oral bioavailability of CoQIO is related to the dissolution rate of the formulation (Kishi et al . , Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan, in: K. Folkers, and Y. Yamamura, eds., Biomedical and Clinical Aspects of Coenzyme Q10, Vol. 4, Elsevier, Amsterdam, 1984,pp. 131-142). Given CoQIO 1 s poor solubility in water, the ability to formulate this substance in a suitable form affording convenient and efficient oral bioavailability is a desired goal.
  • lipids in the form of emulsions, liposomes, icroparticles and nanoparticles
  • These known lipid formulations have comprised particles dispersed in an aqueous medium, and are suitable for various routes of administration, including primarily intravenous administration, as disclosed in: WO 95/05164, which discloses microparticles and nanoparticles in aqueous suspension; US Patent 4,824669, which discloses fatty emulsions; US Patent 4,636,381, which discloses liposomes; and US Patent 4,483,873, which discloses aqueous dispersions or solutions.
  • the neurohormone elatonin is synthesized in the pineal gland with a nocturnal circadian rhythm. Sleep disorders, seasonal depression, mood disorders, migraine, and jet lag are some of the disorders that have been correlated to a disruption of normal, physiological melatonin secretion. There are reports on the beneficial effect of exogenous melatonin administration to reestablish the synchronization of circadian rhythm. However, these studies have shown large variations in oral melatonin absorption, as well as highlighted the inconvenience of employing a continuous intravenous delivery system. Therefore, an oral formulation of melatonin with good bioavailability is needed.
  • a melatonin buccal mucoadhesive sustained release delivery patch mimicking endogenous secretion, has already been shown as one alternative means for delivering melatonin (Benes et al . , Proceed. Intl. Symp. Control. Rel. Bioact. Mater., 21:551-552, 1994).
  • Additional examples of lipophilic drugs with very poor water solubility and low oral bioavailability which could benefit from oral dosage forms are the peptide drug cyclosporin A, the antifungal agent araphotericin B, the anticancer drug etoposide, as well as tamoxifen and its analogs.
  • TPGS vitamin E derivative tocopherol polyethyleneglycol succinate
  • Oily compositions of anti-tumor drugs utilizing TPGS as a solubilizing adjuvant have also been disclosed for instance in US 4578391. Further uses of TPGS as a surface active substance (US 4,668,513), as a cryoprotectant (US 5,198,432) or to improve the bioavailability of vitamin E (US patents 5,179,122 and 5,223,268) have also been disclosed.
  • a powder formulation of water dispersible vitamin E compositions for use as a vitamin E supplement has also been disclosed in US
  • TPGS The structure of TPGS is shown in scheme 2.
  • compositions comprising tocopherol polyethyleneglycol succinate (TPGS) solid coprecipitates useful for the oral delivery of lipophilic substances with low oral bioavailability, and to methods for preparing and using such compositions.
  • TPGS tocopherol polyethyleneglycol succinate
  • the solid coprecipitate compositions of the present invention include a lipophilic substance in an amount sufficient to provide a therapeutic effect when administered to a mammal; tocopherol polyethyleneglycol succinate (TPGS) in an amount sufficient to increase the oral availability of the lipophilic substance; and a dispersion adjuvant in an amount sufficient to assist in dispersing the lipophilic substance in the succinate.
  • TPGS tocopherol polyethyleneglycol succinate
  • the solid TPGS coprecipitates of the present invention comprise a dispersion adjuvant selected from the group consisting of polyvinylpyrrolidone, a medium chain triglyceride, a long chain triglyceride, tocopherol acetate, and polyethyleneglycol.
  • the solid TPGS coprecipitates of the present invention comprise polyvinylpyrrolidone ("PVP") as the dispersion adjuvant.
  • the solid TPGS coprecipitates of the present invention may advantageously further comprise a known freeflow imparting agent, such as fumed silica or the like.
  • a known freeflow imparting agent such as fumed silica or the like.
  • Lipophilic substances incorporated in the powdered TPGS coprecipitates of the present invention have shown unexpectedly improved drug release in simulated gastric fluid in vitro and enhanced oral bioavailability in vivo.
  • the present invention further relates to methods for producing the powdered TPGS coprecipitate compositions, comprising: co-melting TPGS and the lipophilic substance at 40-60°C; adding a dispersion adjuvant to the melted mixture with agitation; adding a fumed silica to the mixture with agitation; and drying the resultant mixture at 100°C to get a dry coprecipitate.
  • the dispersion adjuvant used in accordance with this method may be added as an aqueous solution, an organic cosolvent solution, or an oil.
  • the solid TPGS coprecipitate compositions according to the present invention may be prepared by freeze-drying the TPGS/lipophilic substance/dispersing adjuvant mixture.
  • the solid TPGS coprecipitates compositions according to the present invention may be prepared by spray-drying the TPGS/ lipophilic substance/dispersing adjuvant mixture.
  • the TPGS/ lipophilic substance/dispersing adjuvant coprecipitate formulations can be spray dried or freeze-dried to obtain dry powdered compositions, suitable for the preparation of solid-dosage forms such as hard gelatin capsules or tablets.
  • these solid dosage TPGS coprecipitate compositions are advantageous for the oral delivery of Coenzyme Q10 as a dietary nutrient supplement, melatonin, dexanabinol, amphotericin B, cyclosporin A, etoposide, tamoxifen quaternary amine analogs, or for any appropriate lipophilic substance.
  • FIG. 1 shows the in vitro release patterns of Dexanabinol in simulated gastric fluid from powdered TPGS/PVP solid lipid coprecipitate compositions containing about 2.5 mg drug prepared as described in Example 1 (Table 1) and packed in hard gelatin capsules.
  • FIG. 2 shows the in vitro release patterns of Dexanabinol in simulated gastric fluid from powdered TPGS/PVP/Miglyol solid lipid coprecipitate compositions containing about 2.5 mg drug prepared as described in Example 1 (Table 2) and packed in hard gelatin capsules.
  • FIG. 4 shows the oral pharmacokinetics in rats of Dexanabinol formulated in a solid TPGS lipid coprecipitate (Formulation AY-91-155, Example 1, Table 2) at three different dosages.
  • FIG. 6 shows the in vitro release of CoQIO in simulated gastric fluid from commercial CoQIO gelatin capsules and from a powdered solid TPGS/PVP lipid coprecipitate formulation (ED-107-157, Example 5, Table 5) packed in gelatin capsule.
  • TPGS/PVP lipid coprecipitate formulation ED-107-157, Example 5, Table 5
  • This invention is directed to compositions comprising dry tocopherol polyethyleneglycol succinate solid coprecipitates useful for the oral delivery of lipophilic substances, and to methods for preparing and using such compositions.
  • More specific compounds include cannabinoids, as exemplified by dexanabinol, and vitamins, enzymes or coenzymes, as exemplified by CoQIO.
  • Preferred lipophilic substances are those which have a water solubility of ⁇ 200 ⁇ g/ml in water at room temperature (25°C) , and more preferably ⁇ 50 ⁇ g/ml. Depending on the inherent activity of the active ingredient its quantity has to be adjusted for each specific drug. One of ordinary skill in the art can determine the appropriate concentration by routine testing.
  • compositions according to the invention can contain, for example, as the active lipophilic ingredient: steroids or non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antihistamines, antineoplastics or im unosuppressives.
  • steroids or non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antihistamines, antineoplastics or im unosuppressives.
  • Specific examples would include substances such as clotrimazole, bifonazole, tetracycline, miconazole, triamcinolone, amphotericin, erythromycin hydrocortisone, iodoxuridine, diphenhydramine, minoxidil, lidocaine, tetracaine.
  • drugs are suitable: hypnotics, sedatives, anxiolytices, antidepressants, anticonvulsants, anti-inflammatory drugs, anti-fungals, prostanoids, prostanoid agonists, prostanoid antagonists, analgesics, hormones and vitamins.
  • the active ingredient may be for example Vitamin A, Vitamin E, a polyunsaturated fatty acid such as eicosapentanoic acid, retinoids, carotenes.
  • a wide variety of active ingredients including steroids such as estradiol, progestins, androgens and their antagonists are suitable for formulation according to the present invention.
  • compositions of the present invention are also useful for the enhanced oral availability of certain peptides or proteins such as the hydrophobic or lipophilic peptides exemplified by the immunosuppressive agent cyclosporin.
  • the present invention discloses a novel way to increase the oral bioavailability of any of these lipophilic substances. More particularly, the invention relates to solid coprecipitates comprising the lipophilic substance, a surfactant vehicle having a melting point close to human body temperature, and at least one dispersion agent/adjuvant.
  • TPGS alpha-tocopherol polyethylene glycol succinate
  • TPGS is a water soluble compound (to 20% w/v) and forms micellar solutions with a critical micelle concentration (CMC) of 0.4-0.6 mM/L (about 0.075%).
  • CMC critical micelle concentration
  • HLB hydrophilic-lipophilic balance
  • TPGS is safe for ingestion by humans as a dietary or nutritional supplement.
  • TPGS can be safely used as a surfactant and a bioenhancer for lipophilic substances of limited absorption in gastrointestinal region.
  • the antioxidative properties of TPGS improve the stability of TPGS containing formulations.
  • solid TPGS coprecipitate formulations self-emulsify when dispersed in a aqueous medium, like gastric fluid, forming very small drug mixed-micelles. Lipophilic substances loaded in TPGS solid coprecipitate formulations will be absorbed more easily by the gastrointestinal tract enhancing its oral bioavailability.
  • the solid TPGS coprecipitates of the present invention are composed of three essential ingredients: a lipophilic substance with low water solubility, tocopherol polyethyleneglycol succinate, and at least one dispersion adjuvant.
  • the solid TPGS coprecipitates of the present invention may advantageously further comprise a free-flowing imparting agent, such as fumed silica (Cab-O-Sil, Cabot Corp. , USA) .
  • a free-flowing imparting agent such as fumed silica (Cab-O-Sil, Cabot Corp. , USA) .
  • Lipophilic substances incorporated in the solid TPGS coprecipitates of the present invention have shown unexpectedly improved in vitro drug release in simulated gastric fluid and enhanced oral bioavailability.
  • the lipophilic substance content in the solid TPGS coprecipitates of the present invention may range from about 0.01-50% of the total solid weight of the composition, more preferably in the range of about 5-30% of the total solid weight of the composition, and still more preferably about 10-20% of the total solid weight of the composition.
  • the content of TPGS in the final coprecipitate formulations of the present invention is in the range of about 5-65% of the total solid weight of the composition, more preferably in the range of about 10-60% of the total solid weight of the composition, and still more preferably in the range of about 10-50% of the total solid weight of the composition.
  • the content of dispersion adjuvant in the final coprecipitate formulations of the present invention is in the range of about 5-75% of the total solid weight of the composition, more preferably in the range of about 10-40% of the total solid weight of the composition, and still more preferably in the range of about 10-30% of the total solid weight of the composition.
  • This dispersion adjuvant is included to facilitate the homogeneous dispersion of the lipophilic substance in the mixture.
  • the solid TPGS coprecipitates of the present invention comprise a dispersion adjuvant selected from the group consisting of polyvinylpyrrolidone (PVP) ; a medium chain triglyceride or MCT oil; a long chain triglyceride or LCT oil; tocopherol acetate; polyethyleneglycol; or other adjuvant substance that can improve the dissolution of the lipophilic substance into the mixture or to help the lipophilic substance disperse homogeneously in the TPGS.
  • PVP polyvinylpyrrolidone
  • dispersion adjuvants include: Povidone (ISP Technologies, USA) ; Kollidon 12 PF (BASF, Germany) ; Miglyol 812 (Hulls, Germany) ; LCT oil (Croda) ; and Carbowax 1450 (Union Carbide, USA) .
  • the solid TPGS coprecipitates of the present invention may further comprise any suitable nontoxic carrier or diluent powder known in the art to serve as a free-flow imparting agent.
  • suitable nontoxic carrier or diluent powder known in the art to serve as a free-flow imparting agent.
  • suitable nontoxic carrier or diluent powder known in the art to serve as a free-flow imparting agent.
  • Such additives are silicon dioxide, starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, and dicalcium phosphate.
  • the tablet or pill can be coated or otherwise compounded with pharmaceutically acceptable materials known in the art to provide a dosage form affording prolonged action or sustained release.
  • the solid TPGS coprecipitates may also be prepared in gelatin capsules.
  • solid TPGS coprecipitates are further mixed with fumed silica, such as CAB-O-SIL® (Cabot Corp., IL. , US), which is a powdery material with extremely small particle size and enormous surface area.
  • fumed silica such as CAB-O-SIL® (Cabot Corp., IL. , US), which is a powdery material with extremely small particle size and enormous surface area.
  • Fumed silica can act as a dry lubricant, promoting the free flow of the powdery mixture and preventing the mixture from caking or lumping.
  • the free-flow, anti-caking and anti-clogging characteristics which are imparted to powders, granules and pellets by the addition of small amounts of fumed silica are the result of several actions.
  • the submicroscopic size of the silica aggregates permits them to move easily between the larger particles of the other dry ingredients, and in most cases fumed silica probably forms a coating on the powder particles.
  • the fumed silica layer also decreases bulk tensile strength and shear strength, while neutralizing the electrostatic charge on the particles.
  • fumed silica After blending with the other powders, fumed silica adsorbs some or all the moisture which may be present in or on the product particles.
  • the fumed silica aggregates prevent other particles from contacting each other to form the nuclei that would otherwise lead to the formation of larger lumps and cakes.
  • This spacing and lubricating action helps to keep materials moving through the apertures of process equipment valves, spray heads, storage bin openings, bag and drum spouts, and aerosol nozzle orifices.
  • Most powdered materials can be kept free flowing by adding a concentration of fumed silica in the final product range of about 0.5-25% (total solid weight). The optimum concentration can be determined by working up or down in small steps.
  • the more preferred weight percent of fumed silica in the final product will be in the range of about 1-20% (total solid weight) . Even powders which have already become caked can usually be rendered free flowing by blending them with fumed silica (about 2% of the total solid weight, or less) .
  • Products which cannot be processed beyond a sticky or tacky powder can be made free flowing by adding the proper level of fumed silica as a final finishing step. Fumed silica can also be used to promote free flow in spray-dried or freeze-dried products.
  • the preparation of solid TPGS powdered coprecipitates of lipophilic substances of the present invention may be prepared by different methods as described in the following non-limiting examples.
  • xample l Preparation of tocopherol polyethyleneglycol succinate/polyvinylpyrrolidone powdered coprecipitates of Dexanabinol by freeze-drying.
  • This example illustrates the preparation of tocopherol polyethyleneglycol succinate/polyvinylpyrrolidone (TPGS/PVP) powdered coprecipitates of Dexanabinol by freeze-drying.
  • the final weight/weight % composition of the different formulations prepared were as described in Table 1.
  • TPGS Eastman-Kodak Co., USA
  • PVP Kerdon PF 12, BASF, Germany
  • Dexanabinol was added to the melted materials and the mixtures were gently agitated for several minutes.
  • Cab-O-Sil Cab-O-Sil (Cabot CORP., USA, added from a 5% solution in water) was added and the mixtures were agitated again for several minutes.
  • TPGS/PVP/dexanabinol coprecipitates were formed. The coprecipitates were freeze-dried overnight using a Christ beta lyophilize (Germany) .
  • Powdered free-flowing coprecipitates quickly dispersible in water were obtained.
  • TPGS/PVP/dexanabinol coprecipitates containing additionally tocopherol acetate and Miglyol 812 as described in Table 2 were also prepared by freeze-drying using the same method, which resulted in the formation of powdered free-flowing coprecipitates quickly dispersible in water.
  • the obtained powdered coprecipitates were filled in hard gelatin capsules (No. 1) for in vitro release experiments in simulated gastric fluids and for oral bioavailability studies in rats (minicapsules, Torpac, NJ, USA) .
  • Example 2 Preparation of TPGS/PVP powdered coprecipitates of Dexanabinol by spray-drying
  • This example illustrates the preparation of a TPGS/PVP powdered coprecipitate of Dexanabinol by spray-drying.
  • the final weight/weight % composition of the formulation prepared is described in Table 3:
  • TPGS (249 mg) was melted in a water bath at 50° C.
  • Dexanabinol (249 mg) were then added to the melted TPGS and the mixture was shaken for several minutes at 50° C.
  • PVP (2.2 ml of a 10% solution in water) was added to the comelted mixture of TPGS/Dexanabinol TPGS and the mixture was shaken again for several minutes.
  • Cab-O-Sil 2.3 ml of a 5% solution in water was added and the formulation was shaken again for 1 hr at 50° C.
  • the resultant formulation was spray-dried using a Yamato Pulvis GA32 Mini spray-dryer.
  • the drying conditions were: flow rate 7 ml/min, inlet temperature 130 C°, outlet temperature 80° C, and drying air flow 0.45 m 3 /min.
  • a homogeneous and quickly water-dispersible dry powder of the TPGS/PVP/Dexanabinol coprecipitate was obtained.
  • Example 3 In vitro release of Dexanabinol from solid lipid TPGS coprecipitates in simulated gastric fluid.
  • Dexanabinol was determined by HPLC using a Kontron instrument equipped with pump, UV detector, and autosampler. A summary of the typical chromatographic conditions of the method is provided below:
  • Example 4 Enhanced oral bioavailability of Dexanabinol in solid TPGS coprecipitate formulations.
  • the solid TPGS powdered coprecipitates were filled in hard gelatin minicapsules (Torpac, NJ, USA) and tested for their oral bioavailability in rats.
  • Blood samples were collected at 0,0.5, 1.0, 2.0, 3.0, 5.0, 8.0, and 24 hour time intervals.
  • Plasma samples were centrifuged at 10,000 rpm for 5 min and the plasma was separated and stored frozen at -20° C until plasma Dexanabinol levels were analyzed. Determination of Dexanabinol in the plasma was performed by HPLC. The chromatographic conditions were as described in Example 3. Plasma samples stored at -20° C were defrosted and diluted 1:4 as follows: 150 ⁇ l plasma sample was transferred into a 1.8 ml Eppendorf tube and 150 ⁇ l of acetonitrile were added. The sample was vortexed and centrifuged in a microfuge for 10 minutes at 10,000 rpm. The upper clear liquid was then transferred into an HPLC glass conical vial. A calibration curve was used for calculating Dexanabinol plasma levels. Corrections of sample peak areas were done by subtracting the of average value of the peak area obtained for samples at zero time (blank plasma) .
  • a two fold increase in Dexanabinol plasma levels was obtained with the coprecipitate formulation compared to the oil solution, demonstrating enhanced oral absorption of Dexanabinol from the solid TPGS coprecipitate formulation.
  • This data indicates the good water dispersibility of the formulation, which, in turn, probably facilitates the uptake of the drug from the gastrointestinal tract.
  • Figure 3 shows the rat oral pharmacokinetics of Dexanabinol from TPGS solid lipid coprecipitate formulation (Formulation AY-91-155 prepared as described in Example 1, Table 2) at three different doses. A maximal drug concentration (C ⁇ x ) was obtained after 5 hours (t ⁇ ) for all three doses tested, 10, 25, and 50 mg/kg.
  • Figure 4 illustrates the oral pharmacokinetics of
  • the figure shows increased plasma levels of the drug and demonstrating the improved delivery and oral bioavailability of Dexanabinol.
  • Example 5 Preparation of solid TPGS lipid coprecipitates of Ubiquinone (coenzyme Q10) .
  • Ubiquinone (Coenzyme Q10) was obtained from Global Marketing Associates, Inc. (San Francisco, CA) .
  • the polyethyleneglycol used was Carbowax PEG 1450 from Union Carbide (CT, USA) .
  • the MCT oil (medium chain triglycerides) used was Miglyol 812 (Hulls, Germany) .
  • LCT oil (long chain triglycerides) was from Croda.
  • TPGS/CoQIO coprecipitates were prepared by heating together all the components at 50°-60° C with consequent cooling to room temperature.
  • Compositions containing polyvinylpyrrolidone (PVP K-12) were prepared using 50% PVP solutions in absolute ethanol and drying the obtained mixture at 40°-45° C for 4-6 hours. The obtained TPGS/CoQIO coprecipitates showed quick water dispersibility with rapid release of the CoQIO.
  • Example 6 Preparation of TPGS/PVP powdered coprecipitates of Ubiquinone (coenzyme Q10) by freeze-drying.
  • TPGS Eastman-Kodak Co. , USA
  • Coenzyme Q10 was added to the melted TPGS and the mixtures were gently agitated for several minutes.
  • PVP Kerdon PF 12, BASF, Germany
  • Cab-O-Sil Cab-O-Sil (Cabot CORP., USA, added from a 5% solution in water) was added and the mixtures were agitated again for several minutes. After cooling to room temperature TPGS/PVP/CoQIO coprecipitates were formed.
  • coprecipitates were freeze-dried overnight using a Christ beta lyophilizer (Germany) . Powdered free-flowing coprecipitates quickly dispersible in water were obtained. They were packed in hard gelatin capsules for in vitro release studies.
  • Example 7 In vitro Release of Coenzyme Q10 from powdered TPGS/PVP coprecipitates in simulated gastric fluid.
  • Figure 5 shows the in vitro release patterns of CoQIO from a powdered TPGS/PVP coprecipitate formulation compared to a commercial product ENERGYCO® CoQIO (Herbamed-Assutech Ltd., Rehovot, Israel) in simulated gastric fluid.
  • CoQIO was determined in the commercial product, the powdered TPGS/PVP coprecipitate formulation, and in the release medium in vitro by extraction with Dole reagent (isopropanol:heptane:water, 45:36:17) by measuring the absorbance at 270 nm using a calibration curve.
  • Dole reagent isopropanol:heptane:water, 45:36:17
  • CoQIO was extracted selectively in Dole heptane upper phase, which was transferred to a quartz cuvette for absorbance measurement.
  • the % release of CoQIO from the marketed product was very low compared to a very quick and significant release from the powdered TPGS/PVP coprecipitate formulation.
  • Each ENERGYCO® CoQIO hard gelatin capsule contains 50 mg of CoQIO mixed with rice powder. After capsule disruption in the simulated gastric fluid, big aggregates or clusters of CoQIO and swelled rice powder were observed. These observations may explain the low CoQIO dissolution into the release medium.
  • Example 8 Preparation of TPGS/PVP powdered coprecipitate of Melatonin.
  • TPGS 500 mg was melted at 40°-60° C in a water bath.
  • Melatonin 100 mg, from Jansenn Chimica, Belgium
  • PVP Kinollidon PF 12, 2.6 ml of a 10% solution in water
  • Cab-O-Sil 2.8 ml of a 5% solution in water
  • TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) .
  • a powdered free-flowing TPGS/PVP/melatonin coprecipitate quickly dispersible in water was obtained.
  • Example 9 Preparation of TPGS/PVP powdered coprecipitate of Amphotericin B.
  • TPGS 500 mg was melted at 40°-60° C in a water bath.
  • Amphotericin B 100 mg, from Dumex, Denmark was added to the melted material and the mixture was agitated for several minutes.
  • a small amount of absolute ethanol up to 5%, v/v was added in order to get an homogeneous mixture.
  • TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) .
  • a powdered free-flowing TPGS/PVP/Amphotericin B coprecipitate quickly dispersible in water was obtained.
  • Example 10 Preparation of TPGS/PVP powdered coprecipitate of Tamoxifen methyliodide.
  • TPGS 500 mg was melted at 40°-60° C in a water bath.
  • Tamoxifen methiodide 100 mg, from Phar os Corp., FL, USA
  • PVP Kinollidon PF 12, 2.6 ml of a 10% solution in water
  • Cab-O-Sil 2.8 ml of a 5% solution in water
  • TPGS/PVP/Tamoxifen methiodide mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) .
  • a powdered free-flowing TPGS/PVP/melatonin coprecipitate quickly dispersible in water was obtained.
  • Example 11 Preparation of TPGS/PVP powdered coprecipitate of Etoposide.
  • TPGS 500 mg was melted at 40°-60° C in a water bath.
  • Etoposide 100 mg, from Sigma, St. Louis, USA was added to the melted material and the mixture was agitated for several minutes.
  • a small amount of absolute ethanol up to 5%, v/v was added in order to get an homogeneous mixture.
  • TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) . A powdered free-flowing TPGS/PVP/Etoposide coprecipitate quickly dispersible in water was obtained.
  • Example 12 Preparation of TPGS/PVP powdered coprecipitate of Clycosporin A by freeze-drying.
  • This example illustrates the preparation of tocopheryl polyethylenegylcol succinate powered coprecipitate of the peptide drug cyclosporin A, a very lipophilic undecapeptide with very low water solubility and poor oral bioavailability, by freeze-drying.
  • the final weight/weight % composition of the formulations prepared was as described in Table 6:
  • Table 6 Weight/weight % composition of TPGS/PVP/Cyclosporin A coprecipitate formulation prepared by freeze-drying.
  • lipid components and cyclosporin were dissolved in ethanol.
  • Cab-O-sil was added from a 5% water dispersion to the ethanolic solution (at a final ethanol:water v/v ratio of 1:1) and the mixture was shaken at 40°C for several minutes. The mixture was then frozen at -30°C for several hours and lyophilized overnight using a Christ lyophilizer (Germany) . Homogeneous dry quick-dispersible power containing the cyclosporin-lipid mixture was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Lipophilic active ingredient are co-melted with tocopherol polyethyleneglycol succinate ('TPGS') and a dispersion adjuvant to obtain solid dry coprecipitate compositions suitable as an oral dosage form. The solid TPGS coprecipitates of lipophilic active ingredients show improved drug release in vitro and enhanced oral bioavailability in vivo.

Description

SOLID COPRECIPZTATES FOR ENHANCED BIOAVAILABILITY OF LIPOPHILIC SUBSTANCES
FIELD OF THE INVENTION The present invention concerns compositions comprising solid coprecipitates for improved oral delivery and enhanced bioavailability of lipophilic substances, and to methods for the preparation and use of these compositions. More particularly, these compositions include tocopherol polyethyleneglycol succinate powdered coprecipitates of lipophilic substances.
BACKGROUND OF THE INVENTION Lipophilic substances possessing low water solubility often have poor oral bioavailability. These substances, being hydrophobic by nature, show wetting difficulties and poor dissolution. These properties obviously represent a rate-limiting step in their absorption from solid oral dosage forms and, in turn, cause a subsequent reduction in their bioavailability.
To address the foregoing issue, these lipophilic substances are usually administered in the form of liquid preparations dissolved in edible oils or formulated in oil-in-water emulsions or microemulsions. Even in these formulations, however, the oral bioavailability of many of them is still very low. Thus, even today, there remains an unresolved need for safe and useful formulations that provide enhanced oral bioavailability for such substances.
Cannabinoids are one example of a family of lipophilic substances with very poor water solubility. Cannabinoids such as Δ'-tetrahydrocannabinol (Δ'-THC) ,
Δ6-tetrahydrocannabinol (Δ6-THC) , Δ9-tetrahydrocannabinol (Δ9-THC) , cannabinol, cannabidiol, and their metabolites, are highly hydrophobic lipid soluble compounds and can be dissolved in aqueous solutions only in the range of a few micrograms/ml or less, depending upon the conditions (Garret and Hunt, J. Phar . Sci., 63:1056-1064,1974). In general, the systemic availability of cannabinoids after oral administration is low and mean estimates of the human bioavailability of tetrahydrocannabinol (THC) following oral ingestion range from 6 to 12% depending on the vehicle used. For example, the maximal plasma levels after oral dosing of 20 mg THC in a sesame oil formulation were around 10 ng/ml (Wall et al . , Clin. Pharmacol. Ther. 34:352-363, 1983) .
Dexanabinol (also denoted HU-211) , is disclosed in US Patents 4,876,276 and 5,521,215, as a synthetic non- psychoactive cannabinoid with novel neuroprotective activity in the multiple-action treatment of brain damage associated with stroke, head trauma, and cardiac arrest. The chemical structure of dexanabinol, (+) -(3S, S) -7-hydroxy-Δ6-tetra hydrocannabinol-1, 1-dimetylheptyl, is shown in Scheme 1.
Figure imgf000004_0001
Scheme 1 Dexanabinol is a very lipophilic compound which is practically insoluble in water (less than 50 μg/ml) and, like other lipophilic drugs, exhibits poor oral bioavailability.
Coenzyme Q10, chemically named 2,3-dimethoxy-5-methyl-6- decaprenyl-l,4-benzoquinone and also known by the names Ubiquinone or Vitamin K, is classified as a fat-soluble quinone, a naturally occurring enzyme. It has been identified as an essential component of the mitochondrial respiratory chain, and, thus, a necessary part of a cell's energy production. More particularly, it constitutes a redox-link between flavoproteins and cytochromes and acts as an electron shuttle controlling the efficiency of oxidative phosphorylation. It is a very lipophilic compound and practically insoluble in water due to its long side chain of 10 isoprenoid units.
CoQIO has been previously identified as a natural antioxidant with potential use as a dietary supplement to protect against age-related degeneration and as an adjuvant vitamin to prevent or treat many disease states.
Supplementary Coenzyme Q10 has reportedly shown beneficial influences in a variety of conditions or diseases, including: periodontal disease, certain blood circulation diseases, impaired memory, fatigue, irregular heartbeat, high blood pressure, immune system impairment, and the aging process.
The recommended daily allowance for coenzyme Q10 has not been determined. Most experts agree, however, that the daily requirement lies somewhere between 30 and 60 milligrams. When treating illnesses, dosages of 100 to 300 milligrams are commonly used.
The oral bioavailability of CoQIO is related to the dissolution rate of the formulation (Kishi et al . , Metabolism of exogenous coenzyme Q10 in vivo and the bioavailability of coenzyme Q10 preparations in Japan, in: K. Folkers, and Y. Yamamura, eds., Biomedical and Clinical Aspects of Coenzyme Q10, Vol. 4, Elsevier, Amsterdam, 1984,pp. 131-142). Given CoQIO1 s poor solubility in water, the ability to formulate this substance in a suitable form affording convenient and efficient oral bioavailability is a desired goal. The art has attempted to address the problem by disclosing formulations of Coenzyme Q10 using lipids, in the form of emulsions, liposomes, icroparticles and nanoparticles, have previously been disclosed. These known lipid formulations have comprised particles dispersed in an aqueous medium, and are suitable for various routes of administration, including primarily intravenous administration, as disclosed in: WO 95/05164, which discloses microparticles and nanoparticles in aqueous suspension; US Patent 4,824669, which discloses fatty emulsions; US Patent 4,636,381, which discloses liposomes; and US Patent 4,483,873, which discloses aqueous dispersions or solutions. The neurohormone elatonin is synthesized in the pineal gland with a nocturnal circadian rhythm. Sleep disorders, seasonal depression, mood disorders, migraine, and jet lag are some of the disorders that have been correlated to a disruption of normal, physiological melatonin secretion. There are reports on the beneficial effect of exogenous melatonin administration to reestablish the synchronization of circadian rhythm. However, these studies have shown large variations in oral melatonin absorption, as well as highlighted the inconvenience of employing a continuous intravenous delivery system. Therefore, an oral formulation of melatonin with good bioavailability is needed. A melatonin buccal mucoadhesive sustained release delivery patch, mimicking endogenous secretion, has already been shown as one alternative means for delivering melatonin (Benes et al . , Proceed. Intl. Symp. Control. Rel. Bioact. Mater., 21:551-552, 1994). Additional examples of lipophilic drugs with very poor water solubility and low oral bioavailability which could benefit from oral dosage forms are the peptide drug cyclosporin A, the antifungal agent araphotericin B, the anticancer drug etoposide, as well as tamoxifen and its analogs.
Water-dispersible vitamin preparations were disclosed in US Patent 3,102,078, wherein the vitamin E derivative tocopherol polyethyleneglycol succinate ("TPGS") was shown to have useful properties as a solubilizing agent. Oily compositions of anti-tumor drugs utilizing TPGS as a solubilizing adjuvant have also been disclosed for instance in US 4578391. Further uses of TPGS as a surface active substance (US 4,668,513), as a cryoprotectant (US 5,198,432) or to improve the bioavailability of vitamin E (US patents 5,179,122 and 5,223,268) have also been disclosed. A powder formulation of water dispersible vitamin E compositions for use as a vitamin E supplement has also been disclosed in US
5,234,695.
The structure of TPGS is shown in scheme 2.
Figure imgf000007_0001
Scheme 2
Thus, there remains a need for new formulations which provide improved oral bioavailability of such compounds. The present invention provides such formulations.
SUMMARY OF THE INVENTION This invention is directed to compositions comprising tocopherol polyethyleneglycol succinate (TPGS) solid coprecipitates useful for the oral delivery of lipophilic substances with low oral bioavailability, and to methods for preparing and using such compositions.
The solid coprecipitate compositions of the present invention include a lipophilic substance in an amount sufficient to provide a therapeutic effect when administered to a mammal; tocopherol polyethyleneglycol succinate (TPGS) in an amount sufficient to increase the oral availability of the lipophilic substance; and a dispersion adjuvant in an amount sufficient to assist in dispersing the lipophilic substance in the succinate.
According to a preferred embodiment of the present invention, the solid TPGS coprecipitates of the present invention comprise a dispersion adjuvant selected from the group consisting of polyvinylpyrrolidone, a medium chain triglyceride, a long chain triglyceride, tocopherol acetate, and polyethyleneglycol. According to a more preferred embodiment, the solid TPGS coprecipitates of the present invention, comprise polyvinylpyrrolidone ("PVP") as the dispersion adjuvant.
According to a most preferred embodiment of the present invention, the solid TPGS coprecipitates of the present invention may advantageously further comprise a known freeflow imparting agent, such as fumed silica or the like. This embodiment provides powdered TPGS coprecipitates particularly useful in the preparation of solid dosage forms for oral administration.
Lipophilic substances incorporated in the powdered TPGS coprecipitates of the present invention have shown unexpectedly improved drug release in simulated gastric fluid in vitro and enhanced oral bioavailability in vivo. The present invention further relates to methods for producing the powdered TPGS coprecipitate compositions, comprising: co-melting TPGS and the lipophilic substance at 40-60°C; adding a dispersion adjuvant to the melted mixture with agitation; adding a fumed silica to the mixture with agitation; and drying the resultant mixture at 100°C to get a dry coprecipitate.
The dispersion adjuvant used in accordance with this method may be added as an aqueous solution, an organic cosolvent solution, or an oil.
According to yet another embodiment, the solid TPGS coprecipitate compositions according to the present invention may be prepared by freeze-drying the TPGS/lipophilic substance/dispersing adjuvant mixture.
According to yet another embodiment, the solid TPGS coprecipitates compositions according to the present invention may be prepared by spray-drying the TPGS/ lipophilic substance/dispersing adjuvant mixture. According to a more preferred embodiment, the TPGS/ lipophilic substance/dispersing adjuvant coprecipitate formulations can be spray dried or freeze-dried to obtain dry powdered compositions, suitable for the preparation of solid-dosage forms such as hard gelatin capsules or tablets.
According to a still more preferred embodiment, these solid dosage TPGS coprecipitate compositions are advantageous for the oral delivery of Coenzyme Q10 as a dietary nutrient supplement, melatonin, dexanabinol, amphotericin B, cyclosporin A, etoposide, tamoxifen quaternary amine analogs, or for any appropriate lipophilic substance.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 shows the in vitro release patterns of Dexanabinol in simulated gastric fluid from powdered TPGS/PVP solid lipid coprecipitate compositions containing about 2.5 mg drug prepared as described in Example 1 (Table 1) and packed in hard gelatin capsules.
FIG. 2 shows the in vitro release patterns of Dexanabinol in simulated gastric fluid from powdered TPGS/PVP/Miglyol solid lipid coprecipitate compositions containing about 2.5 mg drug prepared as described in Example 1 (Table 2) and packed in hard gelatin capsules.
FIG. 3 shows the Dexanabinol rat plasma levels after oral administration (50 mg/kg drug, n=5) of a solid TPGS lipid coprecipitate composition (Formulation AY-91-155, Example 1, Table 2) compared to a MCT oil solution of the drug.
FIG. 4 shows the oral pharmacokinetics in rats of Dexanabinol formulated in a solid TPGS lipid coprecipitate (Formulation AY-91-155, Example 1, Table 2) at three different dosages. FIG. 5 shows the Dexanabinol rat plasma levels after oral administration (30 mg/kg drug, n=5) of a powdered solid TPGS lipid coprecipitate composition (Formulation AY-175-3) prepared as described in Example 1 (Table 1) .
FIG. 6 shows the in vitro release of CoQIO in simulated gastric fluid from commercial CoQIO gelatin capsules and from a powdered solid TPGS/PVP lipid coprecipitate formulation (ED-107-157, Example 5, Table 5) packed in gelatin capsule. DETAILED DESCRIPTION OF THE INVENTION This invention is directed to compositions comprising dry tocopherol polyethyleneglycol succinate solid coprecipitates useful for the oral delivery of lipophilic substances, and to methods for preparing and using such compositions.
Examples of lipophilic substances that exhibit poor oral bioavailability include lipophilic drugs, vitamins, and hormones. These include steroids, steroid antagonists, non-steroidal anti-inflammatory agents, antifungal agents, antibacterial agents, antiviral agents, anticancer agents, anti-hypertensives, anti-oxidants, anti-epileptic agents and anti-depressants among many others. Additional examples of lipophilic drugs with very poor water solubility and low oral bioavailability which could benefit from oral dosage forms are the neurohormone melatonin, the antifungal agent amphotericin B, the anticancer drug etoposide, as well as tamoxifen and its analogs. More specific compounds include cannabinoids, as exemplified by dexanabinol, and vitamins, enzymes or coenzymes, as exemplified by CoQIO. Preferred lipophilic substances are those which have a water solubility of <200μg/ml in water at room temperature (25°C) , and more preferably <50μg/ml. Depending on the inherent activity of the active ingredient its quantity has to be adjusted for each specific drug. One of ordinary skill in the art can determine the appropriate concentration by routine testing.
Compositions according to the invention can contain, for example, as the active lipophilic ingredient: steroids or non-steroidal anti-inflammatory drugs, antibiotics, antifungals, antivirals, antihistamines, antineoplastics or im unosuppressives. Specific examples would include substances such as clotrimazole, bifonazole, tetracycline, miconazole, triamcinolone, amphotericin, erythromycin hydrocortisone, iodoxuridine, diphenhydramine, minoxidil, lidocaine, tetracaine.
For pharmaceutical use, the following categories of drugs are suitable: hypnotics, sedatives, anxiolytices, antidepressants, anticonvulsants, anti-inflammatory drugs, anti-fungals, prostanoids, prostanoid agonists, prostanoid antagonists, analgesics, hormones and vitamins. Specific examples would include lipophilic peptides, barbiturates, benzodiazepines, phenothiazines, cyclosporin, diphenoxylate, tacrine, diclofenac, dexa ethasone, prostaglandins, nifedipine, atropine, verapamil, fentanyl, lipophilic peptides, ketoprofen, phenytoin, miconazole and ketoconazole. For vitamins, the active ingredient may be for example Vitamin A, Vitamin E, a polyunsaturated fatty acid such as eicosapentanoic acid, retinoids, carotenes.
For lipophilic hormones, a wide variety of active ingredients, including steroids such as estradiol, progestins, androgens and their antagonists are suitable for formulation according to the present invention.
The compositions of the present invention are also useful for the enhanced oral availability of certain peptides or proteins such as the hydrophobic or lipophilic peptides exemplified by the immunosuppressive agent cyclosporin. The present invention discloses a novel way to increase the oral bioavailability of any of these lipophilic substances. More particularly, the invention relates to solid coprecipitates comprising the lipophilic substance, a surfactant vehicle having a melting point close to human body temperature, and at least one dispersion agent/adjuvant.
After mixing with body fluids, such as gastric fluid, these compositions undergo quick dissolution with resultant micelle formation or emulsification. A good example of a surfactant vehicle (which can quickly disperse drug coprecipitates) is alpha-tocopherol polyethylene glycol succinate (TPGS) , which was first disclosed in US patent 3,102,078. TPGS is an amphipathic molecule, prepared by the esterification of a hydrophilic polyethylene glycol molecule (usually with a mean molecular weight 1000, and about 20-25 ethylene oxide chains) with the carboxylic group of hydrophobic d-alpha-tocopherol hemisuccinate (acid) . TPGS is a water soluble compound (to 20% w/v) and forms micellar solutions with a critical micelle concentration (CMC) of 0.4-0.6 mM/L (about 0.075%). The hydrophilic-lipophilic balance (HLB) of TPGS is about 15-19. The amphipathic nature of TPGS, high HLB and water solubility, and low CMC make the molecule an excellent emulsifying agent for lipophilic substances. The emulsification and subsequent increase in surface area of the lipophilic substance results in increased gastrointestinal drug absorption and bioavailability.
Toxicological studies have shown that TPGS is safe for ingestion by humans as a dietary or nutritional supplement. In conclusion, TPGS can be safely used as a surfactant and a bioenhancer for lipophilic substances of limited absorption in gastrointestinal region. Moreover, the antioxidative properties of TPGS improve the stability of TPGS containing formulations.
According to the present invention, it now is disclosed that solid TPGS coprecipitate formulations self-emulsify when dispersed in a aqueous medium, like gastric fluid, forming very small drug mixed-micelles. Lipophilic substances loaded in TPGS solid coprecipitate formulations will be absorbed more easily by the gastrointestinal tract enhancing its oral bioavailability.
The solid TPGS coprecipitates of the present invention are composed of three essential ingredients: a lipophilic substance with low water solubility, tocopherol polyethyleneglycol succinate, and at least one dispersion adjuvant.
According to a more preferred embodiment of the present invention, the solid TPGS coprecipitates of the present invention, may advantageously further comprise a free-flowing imparting agent, such as fumed silica (Cab-O-Sil, Cabot Corp. , USA) .
Lipophilic substances incorporated in the solid TPGS coprecipitates of the present invention have shown unexpectedly improved in vitro drug release in simulated gastric fluid and enhanced oral bioavailability. The lipophilic substance content in the solid TPGS coprecipitates of the present invention may range from about 0.01-50% of the total solid weight of the composition, more preferably in the range of about 5-30% of the total solid weight of the composition, and still more preferably about 10-20% of the total solid weight of the composition. The content of TPGS in the final coprecipitate formulations of the present invention is in the range of about 5-65% of the total solid weight of the composition, more preferably in the range of about 10-60% of the total solid weight of the composition, and still more preferably in the range of about 10-50% of the total solid weight of the composition.
The content of dispersion adjuvant in the final coprecipitate formulations of the present invention is in the range of about 5-75% of the total solid weight of the composition, more preferably in the range of about 10-40% of the total solid weight of the composition, and still more preferably in the range of about 10-30% of the total solid weight of the composition. This dispersion adjuvant is included to facilitate the homogeneous dispersion of the lipophilic substance in the mixture.
According to a preferred embodiment of the present invention, the solid TPGS coprecipitates of the present invention comprise a dispersion adjuvant selected from the group consisting of polyvinylpyrrolidone (PVP) ; a medium chain triglyceride or MCT oil; a long chain triglyceride or LCT oil; tocopherol acetate; polyethyleneglycol; or other adjuvant substance that can improve the dissolution of the lipophilic substance into the mixture or to help the lipophilic substance disperse homogeneously in the TPGS. Specific examples of such dispersion adjuvants include: Povidone (ISP Technologies, USA) ; Kollidon 12 PF (BASF, Germany) ; Miglyol 812 (Hulls, Germany) ; LCT oil (Croda) ; and Carbowax 1450 (Union Carbide, USA) .
The solid TPGS coprecipitates of the present invention may further comprise any suitable nontoxic carrier or diluent powder known in the art to serve as a free-flow imparting agent. Common examples of such additives are silicon dioxide, starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, and dicalcium phosphate. When the compound is formulated into a tablet or pill, the tablet or pill can be coated or otherwise compounded with pharmaceutically acceptable materials known in the art to provide a dosage form affording prolonged action or sustained release. The solid TPGS coprecipitates may also be prepared in gelatin capsules.
According to a preferred embodiment, solid TPGS coprecipitates are further mixed with fumed silica, such as CAB-O-SIL® (Cabot Corp., IL. , US), which is a powdery material with extremely small particle size and enormous surface area.
Fumed silica can act as a dry lubricant, promoting the free flow of the powdery mixture and preventing the mixture from caking or lumping. The free-flow, anti-caking and anti-clogging characteristics which are imparted to powders, granules and pellets by the addition of small amounts of fumed silica are the result of several actions. For example, the submicroscopic size of the silica aggregates permits them to move easily between the larger particles of the other dry ingredients, and in most cases fumed silica probably forms a coating on the powder particles. The fumed silica layer also decreases bulk tensile strength and shear strength, while neutralizing the electrostatic charge on the particles.
After blending with the other powders, fumed silica adsorbs some or all the moisture which may be present in or on the product particles. The fumed silica aggregates prevent other particles from contacting each other to form the nuclei that would otherwise lead to the formation of larger lumps and cakes. This spacing and lubricating action helps to keep materials moving through the apertures of process equipment valves, spray heads, storage bin openings, bag and drum spouts, and aerosol nozzle orifices. Most powdered materials can be kept free flowing by adding a concentration of fumed silica in the final product range of about 0.5-25% (total solid weight). The optimum concentration can be determined by working up or down in small steps. The more preferred weight percent of fumed silica in the final product will be in the range of about 1-20% (total solid weight) . Even powders which have already become caked can usually be rendered free flowing by blending them with fumed silica (about 2% of the total solid weight, or less) .
Products which cannot be processed beyond a sticky or tacky powder can be made free flowing by adding the proper level of fumed silica as a final finishing step. Fumed silica can also be used to promote free flow in spray-dried or freeze-dried products.
In some cases it can be introduced into the original emulsion, suspension or solution, or blended in later. Fumed silica has also been used to coat powdered and pelletized products to prevent them from caking later. The content of silicon dioxide in the final solid TPGS coprecipitates is commonly in the range of about 5-20% of the total solid weight of the solid coprecipitate, and more preferably in the range of about 10-20% of the total solid weight of the solid coprecipitate. The preparation of solid TPGS powdered coprecipitates of lipophilic substances of the present invention may be prepared by different methods as described in the following non-limiting examples.
EXAMPLES
xample l: Preparation of tocopherol polyethyleneglycol succinate/polyvinylpyrrolidone powdered coprecipitates of Dexanabinol by freeze-drying.
This example illustrates the preparation of tocopherol polyethyleneglycol succinate/polyvinylpyrrolidone (TPGS/PVP) powdered coprecipitates of Dexanabinol by freeze-drying. The final weight/weight % composition of the different formulations prepared were as described in Table 1.
Table 1. Weight/weight % composition of TPGS/PVP/Dexanabinol coprecipitates
Formulation Code and Ingredients AY-91-169-6 AY-91-175-2 AY-9I- 175-2 AY-91-175-10 AY-91-175-3 AY-91-175-4
TPGS 54 50 40 50 30 ■40
Dexanabinol 6 10 20 20 30 30
PVP 26 26 26 16 26 16
Cab-O-Sil 14 14 14 14 14 14
TPGS (Eastman-Kodak Co., USA) was comelted with PVP (Kollidon PF 12, BASF, Germany, added from a 10% solution in water) at 40-60° C in a water bath. Dexanabinol was added to the melted materials and the mixtures were gently agitated for several minutes. Cab-O-Sil (Cabot CORP., USA, added from a 5% solution in water) was added and the mixtures were agitated again for several minutes. After cooling to room temperature, TPGS/PVP/dexanabinol coprecipitates were formed. The coprecipitates were freeze-dried overnight using a Christ beta lyophilize (Germany) . Powdered free-flowing coprecipitates quickly dispersible in water were obtained. TPGS/PVP/dexanabinol coprecipitates containing additionally tocopherol acetate and Miglyol 812 as described in Table 2 were also prepared by freeze-drying using the same method, which resulted in the formation of powdered free-flowing coprecipitates quickly dispersible in water.
Table 2. Weight/weight % composition of TPGS/PVP/Dexanabinol coprecipitates containing Miglyol and tocopherol acetate.
Figure imgf000017_0001
The obtained powdered coprecipitates were filled in hard gelatin capsules (No. 1) for in vitro release experiments in simulated gastric fluids and for oral bioavailability studies in rats (minicapsules, Torpac, NJ, USA) .
Example 2 : Preparation of TPGS/PVP powdered coprecipitates of Dexanabinol by spray-drying,
This example illustrates the preparation of a TPGS/PVP powdered coprecipitate of Dexanabinol by spray-drying. The final weight/weight % composition of the formulation prepared is described in Table 3:
Table 3. Weight/weight % composition of
TPGS/PVP/Dexanabinol coprecipitate formulation prepared by spray-drying
Figure imgf000017_0002
TPGS (249 mg) was melted in a water bath at 50° C. Dexanabinol (249 mg) were then added to the melted TPGS and the mixture was shaken for several minutes at 50° C. PVP (2.2 ml of a 10% solution in water) was added to the comelted mixture of TPGS/Dexanabinol TPGS and the mixture was shaken again for several minutes. Finally, Cab-O-Sil (2.3 ml of a 5% solution in water) was added and the formulation was shaken again for 1 hr at 50° C.
The resultant formulation was spray-dried using a Yamato Pulvis GA32 Mini spray-dryer. The drying conditions were: flow rate 7 ml/min, inlet temperature 130 C°, outlet temperature 80° C, and drying air flow 0.45 m3/min. A homogeneous and quickly water-dispersible dry powder of the TPGS/PVP/Dexanabinol coprecipitate was obtained.
Example 3 : In vitro release of Dexanabinol from solid lipid TPGS coprecipitates in simulated gastric fluid.
In vitro drug release of Dexanabinol from solid TPGS lipid coprecipitates was determined by placing a hard gelatin capsule No. 1 containing the formulation in 50 ml of simulated gastric fluid (150 mM NaCl, pH 1.2, 37° C, containing 1% Tween 80 as sink) . Gentle stirring was provided by a magnetic bar. Samples were drawn from the release medium at prefixed time intervals and filtered through a 2.7 μm PTFE filter (Whatman).
Dexanabinol was determined by HPLC using a Kontron instrument equipped with pump, UV detector, and autosampler. A summary of the typical chromatographic conditions of the method is provided below:
Column: Merck 50980 supersphere 100RP-18, 75x4 mm, 4 μm. Mobile Phase: 30% phosphate buffer (0.01M KH2P04, pH 3.0): 70% acetonitrile (v/v) . Flow rate: 1 ml/min. Detector wavelength: 280 nm. Injection volume: 20 μl. Column temperature: ambient. Retention time: about 5.8 min. Run time: about 9 min. Figure 1 shows the in vitro release data for TPGS/PVP/ Dexanabinol coprecipitate formulations in simulated gastric fluid. Depending on the specific composition of the formulation, very good Dexanabinol release (from 60-95%) was obtained — mainly during the initial 10-20 min.
Example 4 : Enhanced oral bioavailability of Dexanabinol in solid TPGS coprecipitate formulations.
The solid TPGS powdered coprecipitates were filled in hard gelatin minicapsules (Torpac, NJ, USA) and tested for their oral bioavailability in rats. Male Sprague-Dawley rats (220-260 g, n=4) were administered orally with Dexanabinol formulated either as TPGS coprecipitates as described in Example 1 (Tables 1, 2, and 3) and filled in hard gelatin minicapsules (Torpac, NJ, USA) or in a MCT oil solution at 10, 25, and 50 mg/kg doses. Blood samples were collected at 0,0.5, 1.0, 2.0, 3.0, 5.0, 8.0, and 24 hour time intervals. The samples were centrifuged at 10,000 rpm for 5 min and the plasma was separated and stored frozen at -20° C until plasma Dexanabinol levels were analyzed. Determination of Dexanabinol in the plasma was performed by HPLC. The chromatographic conditions were as described in Example 3. Plasma samples stored at -20° C were defrosted and diluted 1:4 as follows: 150 μl plasma sample was transferred into a 1.8 ml Eppendorf tube and 150 μl of acetonitrile were added. The sample was vortexed and centrifuged in a microfuge for 10 minutes at 10,000 rpm. The upper clear liquid was then transferred into an HPLC glass conical vial. A calibration curve was used for calculating Dexanabinol plasma levels. Corrections of sample peak areas were done by subtracting the of average value of the peak area obtained for samples at zero time (blank plasma) .
Figure 2 shows the oral pharmacokinetics of Dexanabinol administered to rats (n=5) at a 50 mg/kg dose as a solid TPGS lipid coprecipitate (Formulation AY-91-155 prepared as described in Example 1, Table 2) compared to a solution of the drug in MCT oil (Miglyol 812) . A two fold increase in Dexanabinol plasma levels was obtained with the coprecipitate formulation compared to the oil solution, demonstrating enhanced oral absorption of Dexanabinol from the solid TPGS coprecipitate formulation. This data indicates the good water dispersibility of the formulation, which, in turn, probably facilitates the uptake of the drug from the gastrointestinal tract.
Figure 3 shows the rat oral pharmacokinetics of Dexanabinol from TPGS solid lipid coprecipitate formulation (Formulation AY-91-155 prepared as described in Example 1, Table 2) at three different doses. A maximal drug concentration (Cωx) was obtained after 5 hours (t^) for all three doses tested, 10, 25, and 50 mg/kg. Figure 4 illustrates the oral pharmacokinetics of
Dexanabinol administered to rats (n=5) at a 30 mg/kg dose as a powdered solid TPGS/PVP lipid coprecipitate in hard gelatin minicapsules (Formulation AY-175-3 prepared as described in Example 1, Table 1) . The figure shows increased plasma levels of the drug and demonstrating the improved delivery and oral bioavailability of Dexanabinol.
Example 5 : Preparation of solid TPGS lipid coprecipitates of Ubiquinone (coenzyme Q10) .
This example illustrates the preparation of tocopherol polyethyleneglycol succinate coprecipitates of Coenzyme Q10. The final weight/weight % composition of the different formulations prepared is described in Table 4:
Table 4. Weight/weight % composition of TPGS/CoQIO coprecipitates .
Formulation Code and Ingredients 106-19B 106-19C 106-16A 106-11C
TPGS 20 21 47.1 47.5
Coenzyme Q10 5 5 5.8 5
MCT oil 75 - -
LCT oil - 74 - -
PVP - - 47.1 -
PEG 1450 - - 47.5
Ubiquinone (Coenzyme Q10) was obtained from Global Marketing Associates, Inc. (San Francisco, CA) . The polyethyleneglycol used was Carbowax PEG 1450 from Union Carbide (CT, USA) . The MCT oil (medium chain triglycerides) used was Miglyol 812 (Hulls, Germany) . LCT oil (long chain triglycerides) was from Croda. TPGS/CoQIO coprecipitates were prepared by heating together all the components at 50°-60° C with consequent cooling to room temperature. Compositions containing polyvinylpyrrolidone (PVP K-12) were prepared using 50% PVP solutions in absolute ethanol and drying the obtained mixture at 40°-45° C for 4-6 hours. The obtained TPGS/CoQIO coprecipitates showed quick water dispersibility with rapid release of the CoQIO.
Example 6: Preparation of TPGS/PVP powdered coprecipitates of Ubiquinone (coenzyme Q10) by freeze-drying.
This example illustrates the preparation of tocopherol polyethyleneglycol succinate powdered coprecipitates of Coenzyme Q10 by freeze-drying. The final weight/weight % composition of the different formulations prepared is described in Table 5: Table 5. Weight/weight % composition of
TPGS/PVP/CoQIO powdered coprecipitates.
Formulation Code and Ingredients ED- 107- 157 ED- 107- 155-1 ED-107-I55-B AY-91-175-C
TPGS 40 56 50 66
Coenzyme Q10 9 13 11 15
PVP 41 15 25 -
Cab-O-Sil 10 16 14 19
TPGS (Eastman-Kodak Co. , USA) was melted at 40°-60° C in a water bath. Coenzyme Q10 was added to the melted TPGS and the mixtures were gently agitated for several minutes. PVP (Kollidon PF 12, BASF, Germany) was then added from a 30% solution in water and the mixtures were shaken at 40° C for 1-2 hr. Cab-O-Sil (Cabot CORP., USA, added from a 5% solution in water) was added and the mixtures were agitated again for several minutes. After cooling to room temperature TPGS/PVP/CoQIO coprecipitates were formed. The coprecipitates were freeze-dried overnight using a Christ beta lyophilizer (Germany) . Powdered free-flowing coprecipitates quickly dispersible in water were obtained. They were packed in hard gelatin capsules for in vitro release studies.
Example 7 : In vitro Release of Coenzyme Q10 from powdered TPGS/PVP coprecipitates in simulated gastric fluid.
In vitro drug release of CoQIO from a powdered TPGS/PVP coprecipitate formulation and from a commercial product containing equivalent amounts of CoQIO were determined by placing a hard gelatin capsule in 50 ml of simulated gastric fluid (150 mM NaCl, pH 1.2, 37° C) containing 1% Tween 80 as sink. Gentle stirring was provided by a magnetic bar. Samples were drawn from the release medium at prefixed time intervals, filtered through a 2.7 μm Whatman GF filter and analyzed for CoQIO concentration. Figure 5 shows the in vitro release patterns of CoQIO from a powdered TPGS/PVP coprecipitate formulation compared to a commercial product ENERGYCO® CoQIO (Herbamed-Assutech Ltd., Rehovot, Israel) in simulated gastric fluid. CoQIO was determined in the commercial product, the powdered TPGS/PVP coprecipitate formulation, and in the release medium in vitro by extraction with Dole reagent (isopropanol:heptane:water, 45:36:17) by measuring the absorbance at 270 nm using a calibration curve. CoQIO samples (0.5 ml) were added to 3.5 ml of Dole reagent and mixed thoroughly. The two phases were then allowed to separate for 10 min at room temperature. CoQIO was extracted selectively in Dole heptane upper phase, which was transferred to a quartz cuvette for absorbance measurement. The % release of CoQIO from the marketed product was very low compared to a very quick and significant release from the powdered TPGS/PVP coprecipitate formulation. Each ENERGYCO® CoQIO hard gelatin capsule contains 50 mg of CoQIO mixed with rice powder. After capsule disruption in the simulated gastric fluid, big aggregates or clusters of CoQIO and swelled rice powder were observed. These observations may explain the low CoQIO dissolution into the release medium. Since particle size is a determinant factor in the rate and extent of drug absorption from the gastrointestinal tract, this result indicates low oral bioavailability of CoQIO from the commercial product compared to powdered TPGS/PVP coprecipitate formulation of the present invention, which is quickly dispersible in the simulated gastric fluid.
Example 8: Preparation of TPGS/PVP powdered coprecipitate of Melatonin.
TPGS (500 mg) was melted at 40°-60° C in a water bath. Melatonin (100 mg, from Jansenn Chimica, Belgium) was added to the melted material and the mixture was agitated for several minutes. A small amount of absolute ethanol (up to 5%, v/v) was added in order to get an homogeneous mixture. PVP (Kollidon PF 12, 2.6 ml of a 10% solution in water) was then added and the mixture was agitated again for several minutes. Cab-O-Sil (2.8 ml of a 5% solution in water) was added and the mixture was agitated again for several minutes. The resultant TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) . A powdered free-flowing TPGS/PVP/melatonin coprecipitate quickly dispersible in water was obtained.
Example 9: Preparation of TPGS/PVP powdered coprecipitate of Amphotericin B.
TPGS (500 mg) was melted at 40°-60° C in a water bath. Amphotericin B (100 mg, from Dumex, Denmark) was added to the melted material and the mixture was agitated for several minutes. A small amount of absolute ethanol (up to 5%, v/v) was added in order to get an homogeneous mixture. PVP
(Kollidon PF 12, 2.6 ml of a 10% solution in water) was then added and the mixture was agitated again for several minutes. Cab-O-Sil (2.8 ml of a 5% solution in water) was added and the mixture was agitated again for several minutes. The resultant TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) . A powdered free-flowing TPGS/PVP/Amphotericin B coprecipitate quickly dispersible in water was obtained.
Example 10: Preparation of TPGS/PVP powdered coprecipitate of Tamoxifen methyliodide.
TPGS (500 mg) was melted at 40°-60° C in a water bath. Tamoxifen methiodide (100 mg, from Phar os Corp., FL, USA) was added to the melted material and the mixture was agitated for several minutes. A small amount of absolute ethanol (up to 5%, v/v) was added in order to get an homogeneous mixture. PVP (Kollidon PF 12, 2.6 ml of a 10% solution in water) was then added and the mixture was agitated again for several minutes. Cab-O-Sil (2.8 ml of a 5% solution in water) was added and the mixture was agitated again for several minutes. The resultant TPGS/PVP/Tamoxifen methiodide mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) . A powdered free-flowing TPGS/PVP/melatonin coprecipitate quickly dispersible in water was obtained.
Example 11: Preparation of TPGS/PVP powdered coprecipitate of Etoposide.
TPGS (500 mg) was melted at 40°-60° C in a water bath. Etoposide (100 mg, from Sigma, St. Louis, USA) was added to the melted material and the mixture was agitated for several minutes. A small amount of absolute ethanol (up to 5%, v/v) was added in order to get an homogeneous mixture. PVP
(Kollidon PF 12, 2.6 ml of a 10% solution in water) was then added and the mixture was agitated again for several minutes. Cab-O-Sil (2.8 ml of a 5% solution in water) was added and the mixture was agitated again for several minutes. The resultant TPGS/PVP/melatonin mixture was then freeze-dried overnight using a Christ beta lyophilizer (Germany) . A powdered free-flowing TPGS/PVP/Etoposide coprecipitate quickly dispersible in water was obtained.
Example 12: Preparation of TPGS/PVP powdered coprecipitate of Clycosporin A by freeze-drying.
This example illustrates the preparation of tocopheryl polyethylenegylcol succinate powered coprecipitate of the peptide drug cyclosporin A, a very lipophilic undecapeptide with very low water solubility and poor oral bioavailability, by freeze-drying. The final weight/weight % composition of the formulations prepared was as described in Table 6:
Table 6 , Weight/weight % composition of TPGS/PVP/Cyclosporin A coprecipitate formulation prepared by freeze-drying.
Formulation Code and Ingredients ED-119-148
TPGS 50
Cyclosporin A 10
PVP 26
Cab-O-Sil 14
All lipid components and cyclosporin were dissolved in ethanol. Cab-O-sil was added from a 5% water dispersion to the ethanolic solution (at a final ethanol:water v/v ratio of 1:1) and the mixture was shaken at 40°C for several minutes. The mixture was then frozen at -30°C for several hours and lyophilized overnight using a Christ lyophilizer (Germany) . Homogeneous dry quick-dispersible power containing the cyclosporin-lipid mixture was obtained.
It will be appreciated by the artisan that many additional modifications or variations of these compositions are feasible. The scope of the invention is, therefore, not to be construed as limited to the foregoing examples, but is to be construed, at the very least, to be commensurate with the scope of the following claims.

Claims

THE CLAIMSWhat is claimed is:
1. A solid coprecipitate composition comprising: a lipophilic substance in an amount sufficient to provide a therapeutic effect when administered to a mammal; tocopherol polyethyleneglycol succinate (TPGS) in an amount sufficient to increase the oral availability of the lipophilic substance; and a dispersion adjuvant in an amount sufficient to assist in dispersing the lipophilic substance in the succinate.
2. The composition of claim 1 wherein the dispersion adjuvant is selected from the group consisting of a polyvinylpyrrolidone, a medium chain triglyceride, a long chain triglyceride, a polyethyleneglycol, and a tocopherol acetate.
3. The composition of claim 1 which further comprises a solid carrier or diluent.
4. The composition of claim 1 wherein the tocopherol polyethyleneglycol succinate comprises about 5-65% of the total solid weight of the composition.
5. The composition of claim 1 wherein the lipophilic substance comprises about 0.01-50% of the total solid weight of the composition.
6. The composition of claim 1 wherein the dispersion adjuvant comprises about 5-75% of the total solid weight of the composition.
7. The composition of claim 1 wherein the dispersion adjuvant is polyvinylpyrrolidone.
8. The composition of claim 7 which further comprises a second dispersion adjuvant selected from the group consisting of an MCT oil, an LCT oil, a polyethylene glycol, and a tocopherol acetate.
9. The composition of claim 3 wherein the solid carrier comprises fumed silicon dioxide in the amount of about 1-20% of the total solid weight of the composition.
10. The composition of claim 1, wherein the composition is present in a unit dosage form.
11. The composition of claim 10 wherein the solid dosage form is selected from the group consisting of a gelatin capsule and a tablet.
12. The composition of claim 1 wherein the lipophilic substance is a drug.
13. The composition of claim 1 wherein the lipophilic substance is selected from the group consisting of a vitamin, a hormone, a peptide and protein.
14. The composition of claim 1 wherein the lipophilic substance is selected from the group consisting of a steroid, steroid antagonist, non-steroidal anti-inflammatory agent, antifungal agent, antibacterial agent, antiviral agent, anticancer agent, anti-hypertensive agent, anti-oxidant agent, anti-epileptic agent, anti-depressant agent and peptide drug.
15. The composition of claim 1 wherein the lipophilic substance is selected from the group consisting of dexanabinol, etoposide, coenzyme Q10, melatonin, cyclosporin A, amphotericin, tamoxifen and tamoxifen methiodide.
16. A method for preparing the solid coprecipitate of claim 1, comprising: comelting the TPGS and the lipophilic substance at about 40°-60°C; adding the dispersion adjuvant to the melted mixture with agitation; and drying the resultant mixture to obtain a dry coprecipitate .
17. The method of claim 16 in which the drying is achieved by spray drying or freeze drying of the mixture.
18. The method of claim 16 wherein the dispersion adjuvant comprises a solution of a polyvinyl pyrrolidone.
19. The method of claim 16 which further comprises adding fumed silica to the mixture of TPGS, lipophilic substance and dispersion adjuvant with agitation.
20. A method for delivering a lipophilic substance to a mammal in need of such a substance which comprises orally administering a therapeutically effective amount of the solid coprecipitate of claim 1.
21. The method of claim 20 wherein said coprecipitate is administered to a mammal having brain damage, periodontal disease, a blood circulation disease, impaired memory, fatigue, an irregular heartbeat, an immune system impairment, aging, a sleep disorder, a mood disorder, a migraine, or a fungal condition.
22. The method of claim 21 wherein the blood circulation disease is high blood pressure or the fatigue is jet lag.
23. The method of claim 20 wherein the coprecipitate comprises as the lipophilic substance an agent selected from the group consisting of dexanabinol, etoposide, coenzyme Q10, cyclosporin A, melatonin, amphotericin, tamoxifen and tamoxifen methiodide.
PCT/US1997/015072 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances WO1998008490A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP51187998A JP2001523221A (en) 1996-09-01 1997-08-27 Solid co-precipitates for enhanced bioavailability of lipophilic substances
CA002264718A CA2264718C (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances
AU42373/97A AU730216B2 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances
EP97940639A EP1017366A4 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL119176 1996-09-01
IL11917696A IL119176A (en) 1996-09-01 1996-09-01 Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
US08/833,076 1997-04-02
US08/833,076 US5891469A (en) 1997-04-02 1997-04-02 Solid Coprecipitates for enhanced bioavailability of lipophilic substances

Publications (1)

Publication Number Publication Date
WO1998008490A1 true WO1998008490A1 (en) 1998-03-05

Family

ID=26323300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/015072 WO1998008490A1 (en) 1996-09-01 1997-08-27 Solid coprecipitates for enhanced bioavailability of lipophilic substances

Country Status (5)

Country Link
EP (1) EP1017366A4 (en)
JP (1) JP2001523221A (en)
AU (1) AU730216B2 (en)
CA (1) CA2264718C (en)
WO (1) WO1998008490A1 (en)

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026607A1 (en) * 1997-11-21 1999-06-03 Fuisz Technologies Ltd. Drug delivery systems utilizing crystal structures
WO1999047175A1 (en) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Pharmaceutical compositions containing melatonin inclusion complexes
WO2000061189A3 (en) * 1999-04-02 2001-01-11 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
WO2001039836A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
JP2002519318A (en) * 1998-06-26 2002-07-02 エルデイエス・テクノロジーズ・インコーポレーテツド Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2002024184A3 (en) * 2000-09-19 2002-07-18 Knoll Gmbh Mechanically stable dosage forms containing ubiquinones
WO2002062392A3 (en) * 2001-02-02 2002-11-14 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
WO2002089773A3 (en) * 2001-05-09 2003-02-06 Novartis Ag Pharmaceutical compositions comprising cyclosporin
JP2003520227A (en) * 2000-01-20 2003-07-02 スプラテック ファーマ インコーポレイテッド Novel podophyllotoxin composition
WO2005058290A2 (en) * 2003-12-18 2005-06-30 Dsm Ip Assets B.V. Vitamin e for facilitating the synchronization of circadian rhythm
WO2006039268A2 (en) * 2004-09-30 2006-04-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
WO2006047067A1 (en) * 2004-10-22 2006-05-04 Eastman Chemical Company Tablets comprising a poorly compressible active agent and tocopherol polyethyleneglycol succinate (tpgs)
WO2008007728A1 (en) * 2006-07-13 2008-01-17 Kaneka Corporation Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2009117152A1 (en) * 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
US7947670B2 (en) 2006-12-12 2011-05-24 Infinity Pharmaceuticals Inc. Ansamycin formulations and methods of use thereof
US8012494B2 (en) 1999-09-13 2011-09-06 Hoffmann-La Roche Inc. Pharmaceutical compositions containing lipase inhibitors
ITMI20112042A1 (en) * 2011-11-10 2013-05-11 Eratech S R L POWDER TO RECONSTITUTE BEFORE INCLUDING MELATONIN AND INJECTABLE PREPARATION OBTAINABLE FROM SUCH POWDER.
CN103190631A (en) * 2008-03-20 2013-07-10 维尔恩公司 Compositions containing non-polar compounds and method for manufacturing phytosterol
US8524696B2 (en) 1999-04-02 2013-09-03 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2014009926A1 (en) 2012-07-12 2014-01-16 Laboratori Guidotti S.P.A. Pediatric oral liquid compositions containing nepadutant
US8722094B2 (en) 2008-03-11 2014-05-13 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
WO2015071837A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9192577B2 (en) 2002-11-29 2015-11-24 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid
WO2015193673A1 (en) * 2014-06-18 2015-12-23 Perioc Limited Novel pharmaceutical formulations and their use in the treatment of periodontal disease
US9320295B2 (en) 2010-03-23 2016-04-26 Virun, Inc. Compositions containing non-polar compounds
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
CN108245683A (en) * 2018-01-26 2018-07-06 华中科技大学 A kind of anti-tumor predrug and preparation method with the inhibition of P- glycoprotein
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US10335385B2 (en) 2010-06-21 2019-07-02 Virun, Inc. Composition containing non-polar compounds
WO2021123108A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. A pyrazole pharmaceutical composition
WO2021123949A1 (en) * 2019-12-20 2021-06-24 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
IT202200002528A1 (en) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composition including highly bioavailable melatonin
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840614B1 (en) * 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US20060115524A1 (en) * 2003-02-19 2006-06-01 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
WO2006036614A2 (en) * 2004-09-24 2006-04-06 Boehringer Ingelheim Pharmaceuticals, Inc. A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer
US7446096B2 (en) * 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
AR075180A1 (en) * 2009-01-29 2011-03-16 Novartis Ag SOLID ORAL FORMULATIONS OF A PYRIDOID-PYRIMIDINONE
JPWO2010092925A1 (en) * 2009-02-12 2012-08-16 あすか製薬株式会社 Solid dispersion, pharmaceutical composition thereof, and production method thereof
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
FR2999081B1 (en) * 2012-12-06 2015-02-27 Hra Pharma Lab SOLID DISPERSION OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR
EP4193990A1 (en) * 2015-05-28 2023-06-14 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
MX2019007968A (en) * 2017-01-03 2019-12-05 Receptor Holdings Inc Medicinal compounds and nutritional supplements.
EP3582755A4 (en) * 2017-02-15 2020-12-23 Molecular Infusions, LLC Formulations
CA3172102A1 (en) * 2020-03-19 2021-09-23 Sonia Maria Poli Dose treatments of tauopathies

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5491154A (en) * 1992-08-05 1996-02-13 Bayer S.P.A. Pharmaceutical preparation for the oral administration of dihydropyridines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU215966B (en) * 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Oral multiple emulsion-preconcentrate containing cyclosporin
CA2221145A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3102078A (en) * 1961-01-13 1963-08-27 Eastman Kodak Co Water-dispersible vitamin preparations
US3673163A (en) * 1970-06-16 1972-06-27 Lilly Co Eli Pharmacological preparation containing an acronycine-polyvinylprrolidone coprecipitate
US4412986A (en) * 1977-06-07 1983-11-01 Yamanouchi Pharmaceutical Co. Ltd. Nifedipine-containing solid preparation composition
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
US5179122A (en) * 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US5234696A (en) * 1991-12-27 1993-08-10 Abbott Laboratories Method of producing tablets, tablets produced thereby, and method of treatment using same
US5491154A (en) * 1992-08-05 1996-02-13 Bayer S.P.A. Pharmaceutical preparation for the oral administration of dihydropyridines
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M.W. ADAMS: "d-Alpha tocopheryl polyethylene glycol 1000 succinate (Eastman Vitamin E TPGS) as an emulsifier and bioenhancer for drugs and lipophilic compounds", INTERNATIONAL CONGRESS OF TECHNOLOGY AND PHARMACOLOGY., ASSOC. PHARM. GALENIQUE IND., CHATENAY MALABRY., FR, vol. 04., no. 4, 1 January 1992 (1992-01-01), FR, pages 254 - 262., XP002011712 *
See also references of EP1017366A4 *
WU S H W, HOPKINGS W, WYATT D: "D-ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 1000 SUCCINATE (TPGS) AS AN ABSORPTION ENHANCER", WORLD MEETING APV/APGI. MEETING ON PHARMACEUTICS,BIOPHARMACEUTICS, PHARMACEUTICAL TECHNOLOGY, XX, XX, 9 May 1995 (1995-05-09), XX, pages 24/25, XP008063660 *
WU W-M, LEE Y-S, BODOR N: "PHARMACOKINETICS, METABOLISM AND EXCRETION OF DELTA1-CORTIENIC ACID ETABONATE AND DELTA1-CORTIENIC ACID, THE METABOLITES OF A SOFT CORTICOSTEROID, LOTEPREDNOL ETABONATE", PHARMACEUTICAL RESEARCH, SPRINGER NEW YORK LLC, US, vol. 11, no. 10, SUPPL., 1 January 1994 (1994-01-01), US, pages S364 + ABSTR. NO. 8127, XP009037847, ISSN: 0724-8741 *

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521421B2 (en) 1997-10-08 2009-04-21 Isotechnika Inc. Deuterated cyclosporine analogs and methods of making the same
US7538189B2 (en) 1997-10-08 2009-05-26 Isotechnika Inc. Methods of making deuterated cyclosporin analogs
US7358229B2 (en) 1997-10-08 2008-04-15 Isotechnika Inc. Deuterated cyclosporin analogs and their use as immunomodulating agents
WO1999026607A1 (en) * 1997-11-21 1999-06-03 Fuisz Technologies Ltd. Drug delivery systems utilizing crystal structures
WO1999047175A1 (en) * 1998-03-13 1999-09-23 Recordati S.A. Chemical And Pharmaceutical Company Pharmaceutical compositions containing melatonin inclusion complexes
JP4875239B2 (en) * 1998-06-26 2012-02-15 アテナ・ニユーロサイエンシズ・インコーポレーテツド Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
JP2002519318A (en) * 1998-06-26 2002-07-02 エルデイエス・テクノロジーズ・インコーポレーテツド Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6200550B1 (en) * 1998-12-11 2001-03-13 Q-Pharma, Inc. Oral care compositions comprising coenzyme Q10
US8524696B2 (en) 1999-04-02 2013-09-03 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US7645816B2 (en) 1999-04-02 2010-01-12 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6191172B1 (en) 1999-04-02 2001-02-20 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2000061189A3 (en) * 1999-04-02 2001-01-11 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
US8012494B2 (en) 1999-09-13 2011-09-06 Hoffmann-La Roche Inc. Pharmaceutical compositions containing lipase inhibitors
WO2001039836A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
JP2003520227A (en) * 2000-01-20 2003-07-02 スプラテック ファーマ インコーポレイテッド Novel podophyllotoxin composition
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US7273624B2 (en) 2000-09-19 2007-09-25 Abbott Gmbh & Co. Kg Stable dosage forms containing ubiquinones
WO2002024184A3 (en) * 2000-09-19 2002-07-18 Knoll Gmbh Mechanically stable dosage forms containing ubiquinones
EP1810694A3 (en) * 2001-02-02 2008-01-09 National Research Council of Canada Water-soluble compositions of bioactive lipophilic compounds
EP1810694A2 (en) * 2001-02-02 2007-07-25 National Research Council of Canada Water-soluble compositions of bioactive lipophilic compounds
WO2002062392A3 (en) * 2001-02-02 2002-11-14 Ca Nat Research Council Water-soluble compositions of bioactive lipophilic compounds
WO2002089773A3 (en) * 2001-05-09 2003-02-06 Novartis Ag Pharmaceutical compositions comprising cyclosporin
US7332472B2 (en) 2001-10-19 2008-02-19 Isotechnika Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US9765119B2 (en) 2001-10-19 2017-09-19 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
USRE48226E1 (en) 2001-10-19 2020-09-29 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US10472394B2 (en) 2001-10-19 2019-11-12 Aurinia Pharmaceuticals Inc. Cyclosporine analogue mixtures and their use as immunomodulating agents
US9192577B2 (en) 2002-11-29 2015-11-24 Janssen Pharmaceutica Nv Pharmaceutical compositions comprising a basic drug compound, a surfactant, and a physiologically tolerable water soluble acid
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
WO2005058290A3 (en) * 2003-12-18 2007-05-10 Dsm Ip Assets Bv Vitamin e for facilitating the synchronization of circadian rhythm
WO2005058290A2 (en) * 2003-12-18 2005-06-30 Dsm Ip Assets B.V. Vitamin e for facilitating the synchronization of circadian rhythm
WO2006039268A2 (en) * 2004-09-30 2006-04-13 Eastman Chemical Company Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
WO2006039268A3 (en) * 2004-09-30 2006-07-27 Eastman Chem Co Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
WO2006047067A1 (en) * 2004-10-22 2006-05-04 Eastman Chemical Company Tablets comprising a poorly compressible active agent and tocopherol polyethyleneglycol succinate (tpgs)
WO2008007728A1 (en) * 2006-07-13 2008-01-17 Kaneka Corporation Oral preparation in the form enclosed in lipid membrane structure, and fatigue-ameliorating agent comprising coenzyme a as active ingredient
US7947670B2 (en) 2006-12-12 2011-05-24 Infinity Pharmaceuticals Inc. Ansamycin formulations and methods of use thereof
US8283343B2 (en) 2006-12-12 2012-10-09 Infinity Pharmaceuticals Inc. Ansamycin formulations and methods of use thereof
US8357676B2 (en) 2006-12-12 2013-01-22 Infinity Discovery, Inc. Ansamycin formulations and methods of use thereof
US8722094B2 (en) 2008-03-11 2014-05-13 Aska Pharmaceutical Co., Ltd. Solid dispersion and pharmaceutical composition of the same, and production processes thereof
EP2548456A1 (en) * 2008-03-20 2013-01-23 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
US9788564B2 (en) 2008-03-20 2017-10-17 Virun, Inc. Compositions containing non-polar compounds
WO2009117152A1 (en) * 2008-03-20 2009-09-24 Virun, Inc. Emulsions including a peg-derivative of tocopherol
CN103190631A (en) * 2008-03-20 2013-07-10 维尔恩公司 Compositions containing non-polar compounds and method for manufacturing phytosterol
US10668029B2 (en) 2008-03-20 2020-06-02 Virun, Inc. Compositions containing non-polar compounds
US8282977B2 (en) 2008-03-20 2012-10-09 Virun, Inc. Compositions containing non-polar compounds
US10220007B2 (en) 2008-03-20 2019-03-05 Virun, Inc. Compositions containing non-polar compounds
US9320295B2 (en) 2010-03-23 2016-04-26 Virun, Inc. Compositions containing non-polar compounds
US10335385B2 (en) 2010-06-21 2019-07-02 Virun, Inc. Composition containing non-polar compounds
ITMI20112042A1 (en) * 2011-11-10 2013-05-11 Eratech S R L POWDER TO RECONSTITUTE BEFORE INCLUDING MELATONIN AND INJECTABLE PREPARATION OBTAINABLE FROM SUCH POWDER.
WO2014009926A1 (en) 2012-07-12 2014-01-16 Laboratori Guidotti S.P.A. Pediatric oral liquid compositions containing nepadutant
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
WO2015071837A1 (en) * 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
WO2015193673A1 (en) * 2014-06-18 2015-12-23 Perioc Limited Novel pharmaceutical formulations and their use in the treatment of periodontal disease
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US10285971B2 (en) 2014-09-18 2019-05-14 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US11246852B2 (en) 2016-12-02 2022-02-15 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
CN108245683A (en) * 2018-01-26 2018-07-06 华中科技大学 A kind of anti-tumor predrug and preparation method with the inhibition of P- glycoprotein
CN108245683B (en) * 2018-01-26 2020-02-14 华中科技大学 Anti-tumor prodrug with P-glycoprotein inhibition function and preparation method thereof
WO2021123108A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. A pyrazole pharmaceutical composition
CN114845702A (en) * 2019-12-20 2022-08-02 英特维特国际股份有限公司 Pyrazole pharmaceutical composition
CN115103668A (en) * 2019-12-20 2022-09-23 爱杜西亚药品有限公司 Pharmaceutical composition comprising N- [1- (5-cyano-pyridin-2-ylmethyl) -1H-pyrazol-3-yl ] -2- [4- (1-trifluoromethyl-cyclopropyl) -phenyl ] -acetamide
WO2021123949A1 (en) * 2019-12-20 2021-06-24 Idorsia Pharmaceuticals Ltd Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide
EP4282475A3 (en) * 2019-12-20 2024-02-28 Intervet International B.V. A pyrazole pharmaceutical composition
CN114845702B (en) * 2019-12-20 2024-03-15 英特维特国际股份有限公司 Pyrazole pharmaceutical composition
IT202200002528A1 (en) * 2022-02-11 2023-08-11 Pierpaoli Exelyas S R L Composition including highly bioavailable melatonin
WO2023152672A1 (en) * 2022-02-11 2023-08-17 Pierpaoli Exelyas S.R.L. Composition comprising melatonin with high bioavailability

Also Published As

Publication number Publication date
EP1017366A4 (en) 2006-03-22
EP1017366A1 (en) 2000-07-12
CA2264718A1 (en) 1998-03-05
AU730216B2 (en) 2001-03-01
JP2001523221A (en) 2001-11-20
CA2264718C (en) 2006-05-30
AU4237397A (en) 1998-03-19

Similar Documents

Publication Publication Date Title
AU730216B2 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) Solid Coprecipitates for enhanced bioavailability of lipophilic substances
AU722217B2 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
AU2002226374B2 (en) Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
KR101234885B1 (en) Compositions forming non-lamellar dispersions
US20250090499A1 (en) Compositions and methods for improving bone health using self-emulsifying formulations of diindolylmethane
JPH08509475A (en) Pharmaceutically acceptable improved composition containing alcohol and hydrophobic drug
JP2001505928A (en) Solid pharmaceutical composition comprising cyclosporin and an anionic surfactant
JP2010090132A (en) Method for producing nanoparticle by fluidized bed spray drying
JP4721640B2 (en) Fenofibrate nanoparticle formulation
WO2003017986A1 (en) Compositions containing itraconazole and their preparation methods
JP2003500454A (en) Substantially oil-free cyclosporin composition
CN100536921C (en) Supersaturated cationic self-emulsifying drug delivery system and preparation method thereof
KR20090086281A (en) Microemulsion Dosage Form of Valsartan and Method of Making the Same
JPH07121858B2 (en) Emulsion composition dehydrated by heat
IL119176A (en) Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
JP2006509785A (en) Oral microemulsion composition of biphenyldimethyldicarboxylic acid
CA2251194C (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
KR100455216B1 (en) Composition for oral administration of poorly soluble antifungal agent and process for the preparation thereof
KR100352089B1 (en) Oral micro-emulsion composition comprising fenofibrate
KR101279568B1 (en) Oral Pharmaceutical Composition Containing Megestrol Acetate
IL126384A (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
SI26054A (en) Super-saturable oil-free self-nanoemulsifying drug delivery system SNEDDS for poorly water-soluble pharmaceutical composition and procedure of preparation thereof
EP3714879A1 (en) Structured encapsulated silicon-containing particles
Yuen et al. 22 Absorption and Disposition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE GH HU IL IS JP KG KP KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264718

Country of ref document: CA

Ref country code: CA

Ref document number: 2264718

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1998 511879

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997940639

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997940639

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载